EP0484500A1 - Komplexes virales antigen von hiv-1 bindendes rekombinantes protein - Google Patents

Komplexes virales antigen von hiv-1 bindendes rekombinantes protein

Info

Publication number
EP0484500A1
EP0484500A1 EP19910910271 EP91910271A EP0484500A1 EP 0484500 A1 EP0484500 A1 EP 0484500A1 EP 19910910271 EP19910910271 EP 19910910271 EP 91910271 A EP91910271 A EP 91910271A EP 0484500 A1 EP0484500 A1 EP 0484500A1
Authority
EP
European Patent Office
Prior art keywords
protein
sc3d6
ser
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910910271
Other languages
German (de)
English (en)
French (fr)
Inventor
Alois Jungbauer
Hermann Katinger
Florian RÜKER
Martin Felgenhauer
Gottfried Himmler
Johann Kohl
Franz Steindl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0484500A1 publication Critical patent/EP0484500A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Definitions

  • Human monoclonal antibodies can be produced by obtaining B lymphocytes from people who show an immune response to an antigen, for example by disease, and immortalizing these B lymphocytes by fusion with suitable cell lines, in particular with myeloma cell lines.
  • Hybrid cell lines obtained in this way, hybridomas serve as production vehicles for mAbs. They can be used in vitro in the form of cell cultures and cultivated to the required scale (1).
  • the substance produced as a rule is a complete mAb, characterized by 2 heavy chains and 2 light chains, which are connected to each other by disulfide bridges and by non-covalent bonds, and form the specifically binding antibody in their community (2).
  • the structure of such an antibody can be divided into a constant region, which is used for the so-called effector functions, e.g. Complement activation, is responsible and in a variable region, which causes the specific binding of the respective antigen.
  • effector functions e.g. Complement activation
  • Antibodies can be cleaved enzymatically using biochemical methods. For example, part of the constant region can be split off by papain or by pepsin. The Fab 'or (Fab') 2 fragments produced in this way are able to bind the relevant antigen in a manner analogous to the original antibody (2). The proteolytic cleavage of the complete constant regions, which leads to a so-called Fv fragment, has also been described. However, it is not nearly as reproducible as the papain or pepsin cleavage of antibodies mentioned above (3, 4). Using genetic engineering methods, however, it is possible to produce Fv fragments in a reproducible manner. The necessary Agile prerequisites and the methods used are described below.
  • RNA is isolated from mAb-producing hybridomas.
  • this RNA contains all of the cell's transcripts.
  • Both incompletely processed nuclear transcripts and mature, cytoplasmic transcripts, the so-called messenger RNAs, are available. These are characterized by a poly adenosine tail at the 3 'end.
  • This poly-A region can be used to isolate the mature mRNAs by affinity chromatography with oligo-dT cellulose.
  • reverse transcriptase the mRNA can be rewritten to a so-called cDNA.
  • the mixture of cDNAs obtained can be cloned using suitable vectors, which leads to a so-called cDNA bank (5).
  • Immunoglobulin-specific hybridization probes allow the identification and isolation of clones which contain the desired sequences). By sequencing the DNA of these clones and comparing them with known imunglobulin genes (EMBL Nucleotide Sequence Data Library, Heidelberg, Germany), certainty about the identity of the clones can be obtained (5). In this way, clones can be isolated, for example, which carry the sequences of the light or heavy chain of a MAK.
  • the individual domains of the heavy or light chain can be identified by comparison with known immunoglobulin sequences: it is possible to identify the variable and the constant region, and e.g. Within the variable region, the so-called “hypervariable” or “complementarity determining regions", which are actually responsible for the specific antigen binding (6).
  • Antibody genes cloned in this way can be expressed in various systems.
  • animal cell cultures can be used, such as Myeloma cells if suitable expression vectors are used (7).
  • yeast (8) or bacterial cells (9) as an expression vehicle for complete antibodies is problematic because such cells. are apparently unable to correctly synthesize the molecules that are very large for them, such as antibodies. Success in this direction only became apparent when an attempt was made to express subfragments of antibodies in lower eukaryotes or in prokaryotes.
  • the plasmid construction used here consists of the Salmonella typhimurium araB promoter and the pelB leader sequence in front of the sequence coding for the respective chain.
  • Antigen-binding Fab fragments were obtained from the culture supernatant of the transformed bacteria.
  • This so-called single-chain Fv fragment was expressed in connection with the MLE leader sequence under the control of the synthetic trp promoter / operator in the form of insoluble inclusion bodies. After their dissolution in 6M guanidine-HCl and removal of the leader by acid hydrolysis between the amino acids Asp and Pro, and after a few chromatography steps, active, antigen-binding single-chain Fv fragment was obtained.
  • Fab ', (Fab') 2 and Fv fragments offer various advantages over complete antibodies. Due to their small size compared to complete antibodies, they can diffuse more easily and quickly, both in vitro and in eventual in vivo applications. For the same reason, they are generally easier to use, and in most cases where the functions of the constant regions (e.g. effector functions, binding to cell receptors, binding to other molecules) are not required or even bring disadvantages, they are equivalent to complete antibodies and, if necessary even preferable. For example, when using complete antibodies in tumor imaging, problems often arise from background signals which are caused by non-specific binding of the antibodies to cell receptors, mediated by the constant regions of the antibodies. It is known that such problems can be reduced using Fab fragments. It can therefore be expected that the use of Fv fragments or single-chain Fv fragments will bring further improvements in this regard (13, 12).
  • the protein of the type mentioned at the beginning contains the antigen-binding regions of an antibody derived from cell line 3D6 (Accession No. 87110301, PHLS, Porton Down, UK (1, 14, 15, 16)). This is the first time that a protein of human origin is obtained which has the desired binding properties and which can also be expressed in single-cell microorganisms, such as yeast or bacteria.
  • This single-chain construction binds to a high-molecular, complex, viral antigen, in contrast to small, well-defined antigens.
  • RNA was isolated.
  • the method of guanidine isothiocyanate extraction and ultracentrifugation over a pad of 5.7M CsCl was used (5).
  • the poly A + fraction that is to say the mRNA, was isolated from the total RNA by adsorption on oligo-dT cellulose. (mRNA purification kit, Pharmacia, Sweden). The mRNA served as a substrate for the synthesis of cDNA (cDNA synthesis kit, from Pharmacia, Sweden). The cDNA library was cloned in the plasmid vector pUC19. The recombinant plasmids were transformed into Escherichia coli, strain HB101 and cultivated on LB medium (5).
  • Positive clones were identified by hybridization with specific oligonucleotide probes.
  • the sequences for the probes were taken from the EMBL DNA sequence database from constant regions of human IgGl heavy or kappa light chains.
  • the clones identified by positive hybridization signals were further characterized by restriction analysis, and those clones which carried the plasmids with the longest inserts were identified.
  • Example 1 In the sequence of the inserts of the clones pUC3D6HC (SEQ ID NO: 1) and ⁇ UC3D6LC (SEQ ID NO: 2), the transition points between the region of the leader peptide and the variable region, and between the variable region and the constant region were identified . The following mutations were carried out at these transition points by oligonucleotide-directed mutagenesis (in vitro mutagenesis system, Amersham, UK) (see also AD): 1) Recognition sequences for certain restriction enzymes were mutated. With the help of these restriction sites, the variable regions of the heavy or the light chain of the antibody 3D6 were cut out of the respective plasmids.
  • two synthetic oligonucleotides were produced which form the two DNA strands of the linker.
  • the two oligonucleotides were chosen so that, when they hybridize with each other, a double-stranded DNA is formed, at the ends of which there are overhanging single-stranded DNA regions which correspond exactly to those overhanging ends which arise when cutting with the corresponding restriction enzymes at the mutated restriction sites mentioned above . This allows the variable regions isolated with the aid of these restriction enzymes to be ligated with the synthetic oligonucleotides of the linker.
  • Dj mutation at the transition between the variable region and the constant region of the light chain of the antibody 3D6 (SEQ ID NO: 2). Mutated bases are marked with "*”. The encoded amino acids in the wild-type DNA are listed, as well as the HindHI restriction site resulting from the mutation and the stop codon TAA.
  • the desired DNA sequence was produced at the transition sites mentioned by a new mutation process (see E and F).
  • sc3D6 single-chain 3D6
  • pUC19 SEQ ID NO: 3
  • the resulting vector is called pUCsc3D6.
  • the sc3D6 gene was excised from the plasmid pUCsc3D6 by restriction enzymes and inserted into the bacterial expression vector pKK223-3 (Pharmacia), which contains the isopropyl-ßthio-galactoside (IPTG) inducible tac promoter.
  • the resulting vector is called DKKSC3D6 and was transformed into the E.coli strain JM105. Cultivation of the bacteria
  • the transformed bacteria were cultivated in a laboratory fermenter up to an OD 600 of 2.0 in LB nutrient medium (5). Expression was then induced by adding isopropylthiogalactoside (IPTG). The bacteria were in for 3 hours
  • This E. coli suspension is incubated at 42 ° C for 15 minutes.
  • the cells are lysed by adding Triton-X-100 (final concentration 0.5%) and again incubating at 42 ° C. for five minutes.
  • the sediment is resuspended in STE buffer and stirred at 4 ° C for 8 h.
  • the inclusion bodies are enriched by centrifugation.
  • a glycerin cushion (50% glycerol / in phosphate buffered saline (PBS)) is placed in centrifuge tubes, covered with the same volume of suspension and centrifuged. (30 minutes, 6000 rpm, 4 ° C, JA-20 rotor, J2-21 centrifuge, Beckman). Loosen the inclusion bodies
  • the enriched inclusion bodies are dissolved in 6M GuHCl (guanidine hydrochloride) in PBS, pH 8.3 with stirring at 4 ° C (12h). The protein content is then determined photometrically.
  • the protein dissolved in GuHCl is refolded in the presence of foreign proteins.
  • the solved Inclusionbodies are with
  • Refolding buffer (GuHCl 1M, glutathione reduced 30mM, glutathione oxidizes 3mM
  • the diluted inclusion bodies are diluted on a laboratory scale using a burette by slowly dropping the protein solution into the refolding buffer. It is best to work at 37 ° C.
  • the folded sc3D6 is ultradiafiltered. A 10,000 Dalton cutoff polysulfone membrane is used. The diafiltered protein solution is applied to an anion exchanger and then eluted from the column with 100 mM NaCl. The sc3D6 is desalted with Sephadex G-25 (Pharmacia, Sweden) gel filtration and according to the method of Nakane et al. (17) conjugated to alkaline phosphatase. The purified sc3D6 protein was checked by SDS-PAGE ( Figure 7).
  • sc3D6 a rabbit serum was produced under standard conditions with complete Freund's adjuvant. With the help of CM-Sepharose Fast Flow Chromatography (Pharmacia, Sweden), the IgG fraction was obtained from the rabbit serum. The specificity of the antibodies was determined by means of ELISA.
  • the 15 amino acid linker peptide (sequence: GGGGSGGGGSGGGGS) was produced with the aid of a peptide synthesizer and then conjugated by means of carbodiimide condensation with bovine serum albumin (BSA) in a molar ratio of 6: 1. Microtiter plates were coated with this conjugate.
  • the serum sample was incubated in the coated microtiter plates and the bound antibody was detected with a peroxidase-labeled goat anti-rabbit IgG.
  • the anti-sc3D6 IgG produced and tested in this way was activated on a BrCN
  • Sepharose 4B (Pharmacia, Sweden) bound.
  • the unbound material was washed out.
  • a pre-purified extract of sc3D6 protein which was refolded as described above and desalted with Sephadex G-25 (from Pharmacia, Sweden), was applied to the anti-sc3D6 column.
  • the unbound material was washed out and the specifically bound sc3D6 protein was washed with a 0.1M glycine HCl
  • the hat was then neutralized with 1M Tris buffer and sc3D6 protein as described on by SDS electrophoresis and checked for functionality by Western blot.
  • a rabbit serum was produced with the aid of complete Freund's adjuvant.
  • the IgG fraction was obtained by CM-Sepharose Fast Flow Chromatography (from Pharmacia, Sweden) and further purified on a BSA-Sepharose 4B column (from Pharmacia, Sweden) in order to remove the anti-BSA antibodies.
  • the anti-linker IgG obtained in this way was coupled to a BrCN-activated Sepharose 4B (from Pharmacia, Sweden).
  • a pre-purified extract of sc3D6 protein which was refolded as described above and desalted with Sephadex G-25 (from Pharmacia, Sweden), was applied to the anti-left column.
  • the unbound material was washed out and the specifically bound sc3D6 protein was eluted with a 0.1M glycine HCl buffer pH 3.0.
  • the eluate was then neutralized with 1M Tris buffer and the sc3D6 protein was characterized by SDS electrophoresis as described and its functionality was checked by Western blot.
  • gpl60 the coat protein of HIV-1, which is specifically bound by the antibody 3D6 and the sc3D6 protein
  • gpl60 the coat protein of HIV-1, which is specifically bound by the antibody 3D6 and the sc3D6 protein
  • the prepurified material containing the recombinant gpl60 was concentrated via ultra / diafiltration and conditioned for sc3D6 immunoaffinity chromatography. This conditioned material was applied to the sc3D6 immunoaffinity column. A 100 mM Tris buffer pH 7.4 with 0.1% Tween 20 was used as the equilibration buffer. The recombinant antigen was eluted with 3M rhodanide. The yields of the individual stages are summarized in Table 2.
  • the sc3D6 gene was excised from the plasmid pUCsc3D6 by restriction enzymes and inserted into the vector pEcphoAMut3 (19). The resulting one
  • Vector is called pAPsc3D6.
  • the vector pEc ⁇ hoAMut3 contains the gene for alkaline phosphatase (20) isolated from Escherichia coli, into which a restriction site has been mutated by oligonucleotide-directed mutagenesis at the 3 'end of the coding region, which permits the fusion of the EcphoA gene with other genes.
  • fusion proteins ie proteins in which the respective coding regions are linked to one another by peptide bonds via amino acids.
  • the EcphoA-sc3D6 fusion gene was cut out of pAPsc3D6 with restriction enzymes and inserted into the bacterial expression vector pKK223-3 (Pharmacia, Sweden). The resulting plasmid is called pKKAPsc3D6.
  • the plasmid pKKAPsc3D6 was transformed into the Escherichia coli strain JM 105 and the transformed bacteria were cultivated in LB nutrient medium (5). After induction with IPTG, active EcPhoA - sc3D6 fusion protein was purified from the periplasmic space of the bacteria as follows:
  • the bacteria are harvested by centrifugation and washed with a 10mM Tris buffer pH 7.5 to which 30mM NaCl has been added.
  • the washed bacteria are resuspended in 33mM Tris buffer pH 7.5 and the same volume of 40% sucrose solution in (33mM Tris buffer) is added and EDTA is added to a final concentration of 0.1mM.
  • the bacteria are centrifuged off and taken up in 0.5 mM MgCl 2 solution.
  • a protease inhibition cocktail consisting of PMSF and EGTA is added and the bacteria are centrifuged off. The supernatant is brought to a final concentration of 25mM Tris with IM Tris solution pH 7.5. This procedure exposes the periplasmic space of the E. coli cells.
  • the protein solution is clarified by centrifugation at 12000 g and then concentrated by ultrafiltration.
  • the EcPhoA - sc3D6 protein is further purified using hydrophobicity interaction chromatography. A phenyl sepharose fast flow (from Pharmacia, Sweden) was included
  • a gpl20-specific monoclonal antibody (clone 25 C2, accession no.
  • Microtiter plates (Grade I, Nunc, Denmark) were coated with a solution of 10 mg / ml recombinant gpl60 (18). The plates were then washed with PBS + 0.1% Tween 20 + 1% BSA. A solution of 5ug / ml EcPhoA - sc3D6 fusion protein was mixed in a ratio of 1: 1 with HTV-1 positive or HIV-1 negative sera and applied to the coated
  • the proportion of bound Ec-PhoaA - sc3D6 protein was detected by adding p-nitrophenyl phosphate. The resulting color was quantified photometrically at 602nm. The inhibition of the sera was determined as a percentage of the absorbance of Ec-PhoA-sc3D6 protein without serum. As shown in Figure 10, all HIV-1 positive sera inhibit the binding of EcPhoA - sc3D6 fusion protein to gp160. All HIV-1 negative sera showed less inhibition than the HTV-1 positive sera.
  • the 3 'part of the sc3D6 gene was isolated from the plasmid ⁇ UCsc3D6 (SEQ ID NO: 3) by partial EcoRV digestion and by complete HindIII digestion (length of the fragment: 401 bp).
  • the 3 'part of the heavy chain gene was removed from plasmid pUC3D6HC (SEQ ID NO: 1) by cutting with EcoRV and Hind.
  • the 401 bp fragment of the sc3D6 gene isolated and purified by agarose gel electrophoresis was inserted into the remaining vector.
  • the gene thus recombined thus consists of the sequence for the leader peptide of the heavy chain of the antibody 3D6, followed by the sequence of the sc3D6 gene.
  • the plasmid is named pLsc3D6.
  • This construction allows the sc3D6 protein to be discharged into animal cells.
  • the coding gene was isolated from pLsc3D6 with the enzymes Ncol and Hindül, the overhanging ends were filled in with Klenow polymerase and cloned into the Smal site of the expression vector pRcRSV (Invitrogen, USA) suitable for animal cells.
  • the site of this expression vector lies between the long terminal repeat of RSV, that is to say a strong viral promoter, and transcription termination sequences which originate from bovine growth hormone. Lisertion into this restriction site makes it possible to bring any structural genes into a molecular environment that allows the expression of the genes in animal cells.
  • the vector pRcRSV also has a selection marker "neomycin resistance", which allows the selection of successfully transformed animal cells in the culture.
  • the plasmid constructed in this way is called pRcRSVLsc3D6. It was transfected into mouse P3-X63-Ag8.653 (21) mouse myeloma cells. After selection of transformed cells with the antibiotic neomycin, a total of 5 clones which express the sc3D6 gene were selected in 2 cloning and screening rounds. The expression levels of the individual clones were tested using an antigen-specific ELISA and are between 0.5 and 1 ⁇ g / ml.
  • the culture supernatant of the transfected mouse myeloma cells containing the sc3D6 protein was fermented by centrifugation at 5000 g in a cup centrifuge.
  • the fermented culture supernatant was concentrated 10-fold by ultrafiltration (Minitan, PTGC, cut off 10,000 Dalton, Millipore) and diafiltered with 5-fold volume with a 50 mM Tris buffer pH 7.2.
  • the diafiltered protein solution was treated with Q-Sepharose Fast Flow (Pharmacia,
  • the plasmid pRcRSVLsc3D6 was transfected into Chinese Hamster Ovary (CHO) cells.
  • transformed cells were selected and screened and the sc3D6 protein was purified from the cell culture supernatant.
  • the expression level was tested by means of an antigen-specific ELISA and the values were between 1 and 5 ⁇ g / ml of antibody.
  • the sc3D6 gene was excised from the plasmid pUCsc3D6 by restriction enzymes and inserted into the yeast expression vector pG1 (Clontech Laboratories Inc., Palo Alto, USA). In this construction, the sc3D6 gene is placed under the regulation of the galactose-inducible GAL1 promoter. The construct was transfected into the Saccharomyces cerevisiae strain SHY2 (trp1-) and selected in medium without tryptophan to complement the tryptophan auxotrophy. Positive transformants were isolated and used to produce sc3D6 protein. The conditions for the cultivation of the production strain and for the isolation, processing and purification of the product were carried out according to standard protocols (22).
  • the sc3D6 gene was excised from the plasmid pUCsc3D6 by restriction enzymes and inserted into the vector pAc373 (23).
  • This recombinant plasmid was transfected together with DNA from the Baculovirus Autographa californica nuclear polyhedrosis virus (AcMNPV) into the cell line Sf9 derived from Spodoptera fhigiperda.
  • Sf9 cells were cultivated according to the standard method as described in the American Type Culture Collection catalog. 3 to 5 days after the transfection, plaques from recombinant viruses were identified microscopically and isolated. To be sure that the recombinant viruses isolated are not wild-type are contaminated, three further plaque cleaning processes were connected.
  • EXAMPLE 7 The sequence (24) coding for the protein avidin was prepared by synthetic oligonucleotides as a synthetic gene, in such a way that the sequence of the leader peptide for E. coli alkaline phosphatase (20) and on the 3rd in addition to the 5 'end of the gene There is a polylinker region for inserting other genes. Genes inserted into this polylinker region are expressed under suitable conditions as fusion proteins with avidin as a fusion partner. With the help of the leader located at the 5 'end, these fusion proteins are actively discharged into the periplasmic space of Escherichia coli.
  • This construct was inserted into a suitable restriction site of the bacterial expression vector pET-3a (25), which contains the bacteriophage T7- ⁇ 10 promoter and the ⁇ terminator for the expression of cloned genes.
  • the resulting vector is called pET-3a-Av.
  • the Bacteriophage T7- ⁇ 10 promoter has the property of not being transcribed in E. coli cells in the absence of the Bacteriophage T7 RNA polymerase. However, if, for example, a tightly grown E. coli culture is infected with a phage vector which carries the genetic information for the T7 polymerase, the T7 polymerase produced thereby leads to the expression of genes which are present, for example, in vectors such as the one described above. This property is very important for the expression of avidin and avidin fusion proteins in E. coli, since the avidin is toxic to growing E. coli cultures.
  • the sc3D6 gene was excised from the vector pUCsc3D6 by restriction enzymes and inserted into the polylinker region of the vector pET-3a-Av.
  • the resulting vector is called pET-3a-Av-sc3D6.
  • Suitable E. coli host cells eg HMS174
  • the bacteriophage CE6 Lambda c ⁇ ts857Sam7 (25)
  • the T7 polymerase thus formed led to the expression of the avidin-sc3D6 fusion protein in the periplasmic space of the E. coli.
  • the recombinant protein was released in an analogous manner to that described in Example 2 and concentrated by ultrafiltration.
  • the concentrated protein solution is further purified over Sephacryl S 200 (Pharmacia) and concentrated a second time by means of ultradiafiltration. This solution is applied to a biotin column. The corresponding fusion protein avidin-sc3D6 remains specifically bound. The impurities are washed out.
  • the affinity column thus produced was used for the purification of recombinant gp160 analogously to Example 1, that is to say the prepurified protein solution according to Barrett et al. (18) was applied to the affinity column and after washing out the unbound material, the recombinant gpl60 was eluted with 3M rhodanide. The yields obtained are analogous to the results shown in Table 2.
  • CHARACTERISTICS from 1 to 21 bp plasmid pUC19 polylinker
  • MOLECULE TYPE Plasmid DNA with insert of engineered human cDNA
  • CHARACTERISTICS from 1 bp to 13 bp plasmid pUC19 polylinker
  • AAA CCA GGG AAA GTC CCT AAG CTC CTG ATC TAT AAG GCA TCT AGT 598 Lys Pro Gly Lys Val Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser
  • Table 3 Yields of the individual stages of the purification of sc3D6 protein from the culture supernatant of transformed mouse myeloma cells.
EP19910910271 1990-05-29 1991-05-28 Komplexes virales antigen von hiv-1 bindendes rekombinantes protein Withdrawn EP0484500A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT117890A AT396939B (de) 1990-05-29 1990-05-29 Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
AT1178/90 1990-05-29

Publications (1)

Publication Number Publication Date
EP0484500A1 true EP0484500A1 (de) 1992-05-13

Family

ID=3508299

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910910271 Withdrawn EP0484500A1 (de) 1990-05-29 1991-05-28 Komplexes virales antigen von hiv-1 bindendes rekombinantes protein

Country Status (7)

Country Link
EP (1) EP0484500A1 (ar)
JP (1) JPH05501062A (ar)
AT (1) AT396939B (ar)
CA (1) CA2064710A1 (ar)
SK (1) SK160391A3 (ar)
WO (1) WO1991018983A1 (ar)
YU (1) YU114691A (ar)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2110295A1 (en) * 1992-03-30 1993-10-14 Tatsuya Kurihara Anti-hbs antibody genes and expression plasmids therefor
US6936705B1 (en) 1993-05-10 2005-08-30 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
WO1994026895A1 (en) * 1993-05-10 1994-11-24 Japan Tobacco Inc. Human immunoglobulin vh gene and dna fragment containing the same
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
KR20010102978A (ko) 1999-01-15 2001-11-17 아스트루 마이클 제이 면역 질환 치료를 위한 트위크 길항약 및 트위크 수용체길항약 및 이들의 용도
WO2001068696A1 (en) * 2000-03-15 2001-09-20 Incyte Genomics, Inc. Human immune response proteins
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
CN102441163A (zh) * 2005-05-27 2012-05-09 比奥根艾迪克Ma公司 结合tweak的抗体
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2238166B1 (en) 2007-10-05 2013-11-27 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
EP0312164A1 (en) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells
WO1989004370A1 (en) * 1987-11-13 1989-05-18 Cl-Pharma Aktiengesellschaft Human monoclonal anti-hiv-i-antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9118983A1 *

Also Published As

Publication number Publication date
CA2064710A1 (en) 1991-11-30
WO1991018983A1 (de) 1991-12-12
AT396939B (de) 1993-12-27
SK160391A3 (en) 1995-07-11
YU114691A (sh) 1994-06-10
ATA117890A (de) 1993-05-15
JPH05501062A (ja) 1993-03-04

Similar Documents

Publication Publication Date Title
AT396939B (de) Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
DE69333044T2 (de) LIGAND-BINDENDE VARIABELE DOMANE (V-MIN), DIE EINE "FRAMEWORK"-REGION ENTHÄLT MIT EINEM ZYKLISCH PERMUTIERTEN ZENTRALEN $g(b)-TUBUS
EP0894135B1 (en) Multivalent and multispecific antigen-binding protein
US6207804B1 (en) Genetically engineered antibody analogues and fusion proteins thereof
DE69433422T2 (de) Monoklonaler anti-hiv antikörper
US5132405A (en) Biosynthetic antibody binding sites
US5091513A (en) Biosynthetic antibody binding sites
DE69535495T2 (de) Expression und exporttechnologie von proteinen als an immunoglobin gebundene fusionsproteine
DE69233008T2 (de) Fusionierung von Peptiden und Proteinen mit Thioredoxin und thioredoxin-ähnlichen Molekülen
JP2594900B2 (ja) マルチチエインポリペプチドまたは蛋白質およびそれらの製造方法
JP2665359B2 (ja) 免疫親和性による精製方法
DE69233068T2 (de) Serin-reiche peptidlinker
EP0335243B1 (en) Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
KR910006602B1 (ko) 면역 인터페론의 제조방법
EP0440147A2 (de) Herstellung und Verwendung von Genbanken menschlicher Antikörper ("Human-Antikörper-Bibliotheken")
JPS58162599A (ja) 雑種ｄｎａおよびそれにより調製される結合性組成物
EP0617706A1 (en) Multivalent antigen-binding proteins
JPH02501192A (ja) 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法
Kurucz et al. A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor.
AU613699B2 (en) Gene fragments coding for anti-hiv antibody variable region, anti-hiv chimeric antibody expressed using the same, and process for preparation thereof
EP1141271B1 (de) Selektion von monoklonalen antikörpern
EP0720623A1 (de) Monoklonale antikörper gegen leukozyten-spezifische g-protein-gekoppelte rezeptoren
AU609128B2 (en) Leukaemia-inhibitory factor
EP1307490B1 (de) Fv-konstrukte mit beeinflussbarer affinitat zu einer zu bindenden substanz
JPH10110000A (ja) 分泌Ｍａｃ−２結合糖タンパク質

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19970416

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970827